ECSP14013201A - Formulaciones parenterales de vacunas contra los norovirus - Google Patents

Formulaciones parenterales de vacunas contra los norovirus

Info

Publication number
ECSP14013201A
ECSP14013201A ECSP14013201A ECSP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A
Authority
EC
Ecuador
Prior art keywords
parenteral formulations
vaccines against
against norovirus
norovirus
compositions
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of ECSP14013201A publication Critical patent/ECSP14013201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ECSP14013201 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus ECSP14013201A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11

Publications (1)

Publication Number Publication Date
ECSP14013201A true ECSP14013201A (es) 2014-05-31

Family

ID=47506489

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013201 ECSP14013201A (es) 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus

Country Status (29)

Country Link
US (5) US9801934B2 (OSRAM)
EP (3) EP2731621B1 (OSRAM)
JP (2) JP6208659B2 (OSRAM)
KR (1) KR102096937B1 (OSRAM)
CN (3) CN105031637A (OSRAM)
AU (2) AU2012282658B2 (OSRAM)
BR (1) BR112014000656A2 (OSRAM)
CA (1) CA2841356C (OSRAM)
CL (1) CL2014000082A1 (OSRAM)
CR (2) CR20190540A (OSRAM)
DK (1) DK3299030T3 (OSRAM)
DO (2) DOP2014000004A (OSRAM)
EA (3) EA202090699A3 (OSRAM)
EC (1) ECSP14013201A (OSRAM)
ES (2) ES2656527T3 (OSRAM)
GE (1) GEP201706668B (OSRAM)
HK (2) HK1199202A1 (OSRAM)
IL (1) IL230356B (OSRAM)
MA (1) MA35414B1 (OSRAM)
MX (2) MX379496B (OSRAM)
MY (1) MY170746A (OSRAM)
PE (1) PE20140845A1 (OSRAM)
PH (3) PH12021551773A1 (OSRAM)
PL (2) PL2731621T3 (OSRAM)
SG (1) SG10201605644WA (OSRAM)
TN (1) TN2014000008A1 (OSRAM)
UA (1) UA117732C2 (OSRAM)
WO (1) WO2013009849A1 (OSRAM)
ZA (2) ZA201401012B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007303608B2 (en) 2006-09-29 2013-05-02 Takeda Vaccines, Inc. Norovirus vaccine formulations
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
DK3299030T3 (da) 2011-07-11 2022-09-05 Takeda Vaccines Inc Parenterale norovirus-vaccineformuleringer
AU2014329403B2 (en) 2013-10-03 2020-10-08 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
AU2018269319A1 (en) * 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11633467B2 (en) 2018-02-15 2023-04-25 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
US20230285534A1 (en) * 2020-01-08 2023-09-14 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
WO2022210742A1 (ja) 2021-03-29 2022-10-06 デンカ株式会社 ノロウイルス由来のペプチド、ポリヌクレオチド、抗体、組成物、ノロウイルスの中和エピトープを同定する方法
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
WO1993021325A1 (en) 1992-04-08 1993-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Wild-type measles virus glycoproteins: vaccine and detection method therefor
JPH08500250A (ja) 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
SI0757717T1 (sl) 1994-05-16 2006-08-31 Merck & Co Inc Cepivo proti papilomavirusu
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
IL132201A0 (en) 1997-04-08 2001-03-19 Merck & Co Inc Stabilized human papillomavirus formulations
JP2002508748A (ja) 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
DE69931053T2 (de) 1998-08-14 2006-11-23 Merck & Co., Inc. Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
EP1140161B1 (en) 1998-12-17 2006-04-19 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
EP1150712B1 (en) 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
CA2783140C (en) 1999-06-22 2016-07-26 Japan As Represented By Directors-General National Institute Of Infectious Diseases Srsv detection kit
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2003219760A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003103605A2 (en) 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
PL375306A1 (en) 2002-06-20 2005-11-28 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
ATE426412T1 (de) 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US20040213745A1 (en) 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
WO2005030806A2 (en) 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP4993301B2 (ja) 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
AU2006203985A1 (en) 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
NZ561040A (en) 2005-03-18 2009-04-30 Cytos Biotechnology Ag Cat allergen fusion proteins and use thereof
EP1885394A4 (en) 2005-06-01 2009-10-21 Dow Global Technologies Inc PRODUCTION OF MULTIVALENT PARTICLES LIKE VIRUSES
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
AU2007303608B2 (en) 2006-09-29 2013-05-02 Takeda Vaccines, Inc. Norovirus vaccine formulations
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
HUE028605T2 (en) * 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
AU2008299589B2 (en) 2007-09-12 2014-06-26 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
WO2010084298A1 (en) * 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use
WO2010092476A1 (en) * 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
EP2525816A4 (en) 2010-01-21 2013-10-02 Ligocyte Pharmaceuticals Inc PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
NO2575876T3 (OSRAM) * 2010-05-26 2018-05-05
DK3299030T3 (da) 2011-07-11 2022-09-05 Takeda Vaccines Inc Parenterale norovirus-vaccineformuleringer
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
EP3389695A4 (en) 2015-12-16 2019-10-09 The Walter and Eliza Hall Institute of Medical Research INHIBITION OF CYTOKININDUCED SH2 PROTEIN IN NK CELLS
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2019213610A1 (en) 2018-05-03 2019-11-07 Board Of Regents, The University Of Texas System Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
JP2021534074A (ja) 2018-08-20 2021-12-09 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Ｖｌｐ製剤
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia

Also Published As

Publication number Publication date
UA117732C2 (uk) 2018-09-25
PE20140845A1 (es) 2014-08-03
SG10201605644WA (en) 2016-09-29
US11701420B2 (en) 2023-07-18
PL3299030T3 (pl) 2022-12-05
NZ620865A (en) 2015-08-28
JP6613259B2 (ja) 2019-11-27
CR20140069A (es) 2014-06-27
EP4112074A1 (en) 2023-01-04
US20160000899A1 (en) 2016-01-07
CR20190540A (es) 2022-04-04
IL230356B (en) 2019-05-30
ZA201401012B (en) 2015-05-27
NZ710919A (en) 2017-12-22
EP2731621A1 (en) 2014-05-21
EP2731621A4 (en) 2015-03-25
MX356586B (es) 2018-06-05
ZA201500915B (en) 2016-06-29
EP2731621B1 (en) 2017-11-01
EA201490258A1 (ru) 2014-05-30
JP2017214357A (ja) 2017-12-07
CN108567975A (zh) 2018-09-25
JP6208659B2 (ja) 2017-10-04
AU2015200836A1 (en) 2015-03-12
EP3299030B1 (en) 2022-06-08
GEP201706668B (en) 2017-05-25
CA2841356A1 (en) 2013-01-17
MA35414B1 (fr) 2014-09-01
BR112014000656A2 (pt) 2017-02-14
US9867876B2 (en) 2018-01-16
EA201792407A3 (ru) 2018-07-31
KR102096937B1 (ko) 2020-04-03
ES2656527T3 (es) 2018-02-27
MX2014000411A (es) 2014-08-26
PH12014500093A1 (en) 2014-03-17
JP2014520852A (ja) 2014-08-25
AU2012282658B2 (en) 2014-11-27
HK1199202A1 (en) 2015-06-26
EA202090699A2 (ru) 2020-07-31
AU2012282658A1 (en) 2013-03-14
DK3299030T3 (da) 2022-09-05
MX379496B (es) 2025-03-11
HK1198136A1 (en) 2015-03-13
PH12021551773A1 (en) 2022-08-01
US20230338503A1 (en) 2023-10-26
US20180185468A1 (en) 2018-07-05
CN103874507A (zh) 2014-06-18
KR20140066160A (ko) 2014-05-30
US10675341B2 (en) 2020-06-09
AU2015200836B2 (en) 2016-08-25
US20130273102A1 (en) 2013-10-17
US9801934B2 (en) 2017-10-31
CA2841356C (en) 2022-03-01
EA035442B1 (ru) 2020-06-17
DOP2022000030A (es) 2022-06-30
EA201792407A2 (ru) 2018-03-30
DOP2014000004A (es) 2014-10-31
PL2731621T3 (pl) 2018-10-31
CL2014000082A1 (es) 2014-07-04
EA202090699A3 (ru) 2020-11-30
TN2014000008A1 (en) 2015-07-01
EP3299030A1 (en) 2018-03-28
HK1215154A1 (zh) 2016-08-19
US20210085778A1 (en) 2021-03-25
CN105031637A (zh) 2015-11-11
EA029470B1 (ru) 2018-03-30
PH12018501515A1 (en) 2019-02-04
ES2926487T3 (es) 2022-10-26
WO2013009849A1 (en) 2013-01-17
MY170746A (en) 2019-08-27
PH12018501515B1 (en) 2022-02-18

Similar Documents

Publication Publication Date Title
ECSP14013201A (es) Formulaciones parenterales de vacunas contra los norovirus
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
MX2018002728A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
AR133161A2 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PE20151588A1 (es) Vacuna contra el virus del dengue
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
EP2825196A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
SG11201401733VA (en) Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
GT201400120A (es) Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina
IN2014MN02275A (OSRAM)
UY35329A (es) Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma.